Our Opinion

Synaptogenix Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company stated in the following press release that they use animals for product testing.

“In a recent Nature publication, co-authored by the Fragile X Research Foundation and Synaptogenix scientists, Bryostatin was shown to successfully treated both Fragile X Cognitive and Autistic Spectrum Disorder Deficits in animal models.” Read the following article

Company Description

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Company Website: https://www.synaptogen.com